Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer medicine"
DOI: 10.1002/cam4.4347
Abstract: Progression-free survival (PFS) has been used as a surrogate endpoint for overall survival (OS) in lung cancer trials. The pattern of response to immune-checkpoint inhibitors (ICIs) differs from that to conventional chemotherapy, so immune-related response… read more here.
Keywords: immune; response; lung cancer; cancer ... See more keywords
Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence
Sign Up to like & getrecommendations! Published in 2022 at "Health Economics"
DOI: 10.1002/hec.4524
Abstract: Abstract In the drive toward faster patient access to treatments, health technology assessment (HTA) agencies and payers are increasingly faced with reliance on evidence based on surrogate endpoints, increasing decision uncertainty. Despite the development of… read more here.
Keywords: endpoint evidence; evidence; decision tool; decision ... See more keywords
Evaluating Clinical Efficacy of Antiviral Therapy for COVID-19: A Surrogate Endpoint Approach
Sign Up to like & getrecommendations! Published in 2021 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-021-00431-9
Abstract: Efficient evaluation with an early surrogate endpoint, taking into account the process of disease evolution, may not only clarify inconsistent or underpowered results but also provide a new insight into the exploration of a new… read more here.
Keywords: covid; surrogate endpoint; high risk; risk ... See more keywords
Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz253.103
Abstract: Abstract Background Combination of ICIs and chemotherapy (ICI-C) has become a more favourable design in recent trials. We have previously reported 6-month PFS rate (PFS6) is a good surrogate for 12-month overall survival rate (OS12)… read more here.
Keywords: pfs; ici; self advisory; honoraria self ... See more keywords
Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes
Sign Up to like & getrecommendations! Published in 2023 at "Diabetes"
DOI: 10.1111/dom.15030
Abstract: For the purpose of predicting clinical outcomes in patients with diabetes and chronic kidney disease, change in albuminuria is a good candidate to be a surrogate marker for future cardiovascular events and progression of kidney… read more here.
Keywords: outcomes patients; renal outcomes; change albuminuria; patients diabetes ... See more keywords
Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-000399
Abstract: Background Epidermal growth factor receptor (EGFR) is one of the most common oncogenes in non-small cell lung cancer (NSCLC). EGFR-tyrosine kinase inhibitor (TKI) and platinum-doublet chemotherapy (PT) are effective regimens in patients with NSCLC harbouring… read more here.
Keywords: cancer; surrogate endpoint; egfr mutations; lung cancer ... See more keywords
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
Sign Up to like & getrecommendations! Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2020-002114
Abstract: Background Progression-free survival (PFS) exhibits suboptimal performance as the surrogate endpoint for overall survival (OS) in trials studying immune checkpoint inhibitors (ICIs). Here we propose a novel surrogate endpoint, modified PFS (mPFS), which omits the… read more here.
Keywords: pfs; mpfs; surrogate endpoint; oncology ... See more keywords
Surrogate Endpoint ID'd for Prostate Cancer Trials.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2017-121
Abstract: Metastasis-free survival is a strong surrogate for overall survival for men with localized prostate cancer, a meta-analysis shows. The intermediate outcome measure could help accelerate the evaluation of novel adjuvant therapies in this patient population. read more here.
Keywords: prostate cancer; cancer trials; cancer; surrogate endpoint ... See more keywords
Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221131526
Abstract: Background: The surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal squamous cell carcinoma (ESCC) remains unelucidated. This study aimed to determine the validity of PFS as a surrogate endpoint for OS in… read more here.
Keywords: survival; pfs; year; surrogate endpoint ... See more keywords
Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.5057
Abstract: 5057 Background: Radiographic progression-free survival (rPFS) is commonly used as a co-primary endpoint in randomized clinical trials in men with metastatic castrate-resistant prostate cancer (mCRPC). However, rPFS has not been established as a valid surrogate… read more here.
Keywords: rpfs; progression; endpoint; surrogate endpoint ... See more keywords
Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data.
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.18853
Abstract: The gold standard endpoint to evaluate the effect of treatment for hepatocellular carcinoma (HCC) is overall survival (OS), but it requires a longer follow-up period to observe. This study aimed to identify whether disease-free survival… read more here.
Keywords: curative treatment; treatment; therapies curative; surrogate endpoint ... See more keywords